Management of Atrial Fibrillation with Rapid Ventricular Response

Immediate Assessment and Treatment

The American College of Cardiology recommends immediate direct-current cardioversion without delay for pharmacological therapy if the patient exhibits severe hypotension or shock, ongoing myocardial ischemia or angina, acute heart failure or pulmonary edema, or symptomatic hypotension not responding promptly to medical management, which is a Class I recommendation (strongest evidence) 2
For hemodynamically stable patients with AF and RVR, the American Heart Association suggests intravenous beta-blockers (metoprolol, esmolol) or non-dihydropyridine calcium channel blockers (diltiazem, verapamil) as first-line agents, with diltiazem achieving rate control faster than metoprolol 1

The European Society of Cardiology recommends beta-blockers as the preferred first-line agents in patients with myocardial ischemia or acute myocardial infarction, coronary artery disease, hyperthyroidism, or preserved left ventricular function (LVEF >40%) 3
The American College of Cardiology suggests non-dihydropyridine calcium channel blockers are preferred in patients with bronchospastic lung disease (asthma, COPD) where beta-blockers are contraindicated, or preserved LVEF without decompensated heart failure 3
The dosing for intravenous beta-blockers is as follows: metoprolol 2.5-5 mg IV bolus over 2 minutes, up to 3 doses, esmolol 0.5 mg/kg IV bolus over 1 minute, then 0.05-0.2 mg/kg/min infusion, and propranolol 0.15 mg/kg IV (or 1 mg IV over 1 minute, up to 3 doses at 2-minute intervals) 5

For patients with Heart Failure with Reduced Ejection Fraction (HFrEF), the American Heart Association recommends using intravenous digoxin or amiodarone as first-line agents, and beta-blockers and calcium channel blockers are contraindicated (Class III: Harm) in decompensated heart failure or cardiogenic shock 6
For patients with pre-excitation syndromes (Wolff-Parkinson-White), the American College of Cardiology suggests immediate direct-current cardioversion for hemodynamically unstable patients, and intravenous procainamide is the drug of choice (Class I recommendation) for stable patients 1

The European Heart Journal recommends target heart rate ranges of 60-80 beats per minute at rest and 90-115 beats per minute during moderate exercise 5

The American College of Cardiology suggests a combination of digoxin and a beta-blocker (or calcium channel blocker for HFpEF patients) is reasonable to control both resting and exercise heart rate when monotherapy is insufficient 2

The American Heart Association recommends AV node ablation with ventricular pacing is reasonable when pharmacological therapy is insufficient or not tolerated, but should not be performed without a prior pharmacological trial to achieve ventricular rate control (Class III: Harm) 6

The American College of Cardiology recommends anticoagulation must be initiated as soon as possible and continued for at least 4 weeks after cardioversion unless contraindicated, with options including IV heparin, low-molecular-weight heparin, or factor Xa/direct thrombin inhibitors 1

The European Heart Journal warns of digoxin limitations, including delayed onset of action, ineffectiveness as monotherapy in acute AF, and potential for worsening heart failure in certain populations 5
The American College of Cardiology cautions against using AV nodal blocking agents in pre-excitation syndrome, as it can precipitate ventricular fibrillation 2